What is the address of Dr. Joris DE KOCK, Reumatologie?

The registered office of Dr. Joris DE KOCK, Reumatologie is located at Hoogstraat 103, 9472 Denderleeuw.

Is Dr. Joris DE KOCK, Reumatologie still active?

Yes. According to the CBE (24 September 2026) Dr. Joris DE KOCK, Reumatologie is active, legal situation “Normale toestand”, started on 12 December 1994.

Is Dr. Joris DE KOCK, Reumatologie registered on Peppol?

No, Dr. Joris DE KOCK, Reumatologie is currently not registered on the Peppol network.

What is the enterprise number of Dr. Joris DE KOCK, Reumatologie?

The enterprise number of Dr. Joris DE KOCK, Reumatologie is BE0454026514.

When was Dr. Joris DE KOCK, Reumatologie founded?

Dr. Joris DE KOCK, Reumatologie was founded on 12 December 1994.

Who are the directors of Dr. Joris DE KOCK, Reumatologie?

According to the 2025 annual accounts, the directors of Dr. Joris DE KOCK, Reumatologie are: Joris De Kock.

Is Dr. Joris DE KOCK, Reumatologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 December 1994; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Joris DE KOCK, Reumatologie make in 2025?

Dr. Joris DE KOCK, Reumatologie posted a profit after taxes of € 88,492 in financial year 2025.

What is the revenue of Dr. Joris DE KOCK, Reumatologie?

As a small company, Dr. Joris DE KOCK, Reumatologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 153,959.

Dr. Joris DE KOCK, Reumatologie (Private Limited)

Dossier Dr. Joris DE KOCK, Reumatologie, printed on 24 September 2026 from databakkes.be/en/0454026514/dr-joris-de-kock-reumatologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Dr. Joris DE KOCK, Reumatologie from Denderleeuw, company number BE0454026514, closed financial year 2025 with a result of € 88,492 after tax. For that financial year Dr. Joris DE KOCK, Reumatologie recorded a gross margin of € 153,959 and equity of € 348,465. Compared with financial year 2024, the result moved from € 73,576 to € 88,492. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Growing

€ 348,465

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 88,492

▲ 20% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 137,513

▲ 19% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 328,005.

People and assets in 2025

Vehicles and equipment

€ 5,161

▲ 57% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 166,073

▲ € 134,160 vs 2024

€ 15,729 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 166

▼ 96% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,849

▼ 18% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 166,047 Gross margin 2022: € 166,047 First fiscal year in the series	€ 96,249 Gross margin 2023: € 96,249 ▼ 42% vs 2022 (€ 166,047) Unfavourable step	€ 122,919 Gross margin 2024: € 122,919 ▲ 28% vs 2023 (€ 96,249) Favourable step	€ 153,959 Gross margin 2025: € 153,959 ▲ 25% vs 2024 (€ 122,919) Favourable step	▲ 25%
Profit after taxes	€ 126,629 Profit after taxes 2022: € 126,629 First fiscal year in the series	€ 47,627 Profit after taxes 2023: € 47,627 ▼ 62% vs 2022 (€ 126,629) Unfavourable step	€ 73,576 Profit after taxes 2024: € 73,576 ▲ 54% vs 2023 (€ 47,627) Favourable step	€ 88,492 Profit after taxes 2025: € 88,492 ▲ 20% vs 2024 (€ 73,576) Favourable step	▲ 20%
Equity	€ 138,771 Equity 2022: € 138,771 First fiscal year in the series	€ 186,397 Equity 2023: € 186,397 ▲ 34% vs 2022 (€ 138,771) Favourable step	€ 259,973 Equity 2024: € 259,973 ▲ 39% vs 2023 (€ 186,397) Favourable step	€ 348,465 Equity 2025: € 348,465 ▲ 34% vs 2024 (€ 259,973) Favourable step	▲ 34%
Total debts	€ 145,599 Total debts 2022: € 145,599 First fiscal year in the series	€ 101,197 Total debts 2023: € 101,197 ▼ 30% vs 2022 (€ 145,599) Favourable step	€ 62,011 Total debts 2024: € 62,011 ▼ 39% vs 2023 (€ 101,197) Favourable step	€ 178,655 Total debts 2025: € 178,655 ▲ 188% vs 2024 (€ 62,011) Unfavourable step	▲ 188%
Cash	€ 114,010 Cash 2022: € 114,010 First fiscal year in the series	€ 28,562 Cash 2023: € 28,562 ▼ 75% vs 2022 (€ 114,010) Unfavourable step	€ 115,562 Cash 2024: € 115,562 ▲ € 87,000 vs 2023 (€ 28,562) Favourable step	€ 137,513 Cash 2025: € 137,513 ▲ 19% vs 2024 (€ 115,562) Favourable step	▲ 19%
Land & buildings	-	-	€ 54,856 Land & buildings 2024: € 54,856 First fiscal year in the series	€ 178,773 Land & buildings 2025: € 178,773 ▲ 226% vs 2024 (€ 54,856) Unchanged	▲ 226%
Retained profit	€ 118,311 Retained profit 2022: € 118,311 First fiscal year in the series	€ 165,937 Retained profit 2023: € 165,937 ▲ 40% vs 2022 (€ 118,311) Favourable step	€ 239,513 Retained profit 2024: € 239,513 ▲ 44% vs 2023 (€ 165,937) Favourable step	€ 328,005 Retained profit 2025: € 328,005 ▲ 37% vs 2024 (€ 239,513) Favourable step	▲ 37%
Bank debt	€ 111,594 Bank debt 2022: € 111,594 First fiscal year in the series	€ 71,471 Bank debt 2023: € 71,471 ▼ 36% vs 2022 (€ 111,594) Favourable step	€ 31,913 Bank debt 2024: € 31,913 ▼ 55% vs 2023 (€ 71,471) Favourable step	€ 166,073 Bank debt 2025: € 166,073 ▲ € 134,160 vs 2024 (€ 31,913) Unfavourable step	▲ € 134,160
Balance sheet total	€ 284,369 Balance sheet total 2022: € 284,369 First fiscal year in the series	€ 287,595 Balance sheet total 2023: € 287,595 ▲ 1% vs 2022 (€ 284,369) Unchanged	€ 321,984 Balance sheet total 2024: € 321,984 ▲ 12% vs 2023 (€ 287,595) Unchanged	€ 527,120 Balance sheet total 2025: € 527,120 ▲ 64% vs 2024 (€ 321,984) Unchanged	▲ 64%

Key figures of Dr. Joris DE KOCK, Reumatologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Joris DE KOCK, Reumatologie?

What happened at Dr. Joris DE KOCK, Reumatologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 10, 2026 New annual accounts for financial year 2025: profit of € 88,492 (▲ 20% vs 2024). Source: NBB ↗
Jan 2, 2017 New establishment in Denderleeuw. KBO
Dec 12, 1994 Start of the company according to the CBE. KBO

In short

From € 126,629 profit in 2022 to € 88,492 profit in 2025.

Paid € 82,644 in corporate taxes since 2022.

Best year ever: 2022, with € 126,629 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Joris DE KOCK, Reumatologie? We notify you, reason included.

Follow Dr. Joris DE KOCK, Reumatologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Joris De Kock

Dr. Joris DE KOCK, Reumatologie

Behind Dr. Joris DE KOCK, Reumatologie is Joris De Kock.

See the full network in the app

Directors

According to the 2025 annual accounts

Joris De Kock

Administrator-manager

Establishments

Establishment units

Physical locations of this company

Registered office

Hoogstraat 103

9472 Denderleeuw

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0454.026.514
VAT number: BE 0454.026.514
Registered office: Hoogstraat 103, 9472 Denderleeuw
Names & denominations: Dr. Joris DE KOCK, Reumatologie · Dr. Joris DE KOCK
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 December 1994
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗